Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Visual and volumetric parameters by 18F-FDG-PET/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma.

Fonti R, Pellegrino S, Catalano L, Pane F, Del Vecchio S, Pace L.

Ann Hematol. 2020 Jan;99(1):127-135. doi: 10.1007/s00277-019-03852-2. Epub 2019 Nov 27.

PMID:
31776725
2.

Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer.

Pellegrino S, Fonti R, Mazziotti E, Piccin L, Mozzillo E, Damiano V, Matano E, De Placido S, Del Vecchio S.

Ann Nucl Med. 2019 Dec;33(12):937-944. doi: 10.1007/s12149-019-01407-z. Epub 2019 Oct 14.

PMID:
31612416
3.

Preclinical Imaging in Targeted Cancer Therapies.

Iommelli F, De Rosa V, Terlizzi C, Fonti R, Del Vecchio S.

Semin Nucl Med. 2019 Sep;49(5):369-381. doi: 10.1053/j.semnuclmed.2019.06.003. Epub 2019 Jun 19. Review.

PMID:
31470932
4.

PET/CT in radiation oncology.

Fonti R, Conson M, Del Vecchio S.

Semin Oncol. 2019 Jun;46(3):202-209. doi: 10.1053/j.seminoncol.2019.07.001. Epub 2019 Jul 26. Review.

PMID:
31378377
5.

Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells.

De Rosa V, Monti M, Terlizzi C, Fonti R, Del Vecchio S, Iommelli F.

Int J Mol Sci. 2019 Jun 27;20(13). pii: E3134. doi: 10.3390/ijms20133134.

6.

Neutrophil Extracellular Traps as an Adhesion Substrate for Different Tumor Cells Expressing RGD-Binding Integrins.

Monti M, De Rosa V, Iommelli F, Carriero MV, Terlizzi C, Camerlingo R, Belli S, Fonti R, Di Minno G, Del Vecchio S.

Int J Mol Sci. 2018 Aug 9;19(8). pii: E2350. doi: 10.3390/ijms19082350.

7.

2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography in primary extranodal lymphomas: treatment response evaluation and prognosis.

Salvatore B, Fonti R, De Renzo A, Pellegrino S, Ferrara IL, Mainolfi CG, Marano L, Selleri C, Pane F, Del Vecchio S, Pace L.

Q J Nucl Med Mol Imaging. 2018 Apr 24. doi: 10.23736/S1824-4785.18.03043-1. [Epub ahead of print]

PMID:
29697219
8.

Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non-Small Cell Lung Cancer Detected by 18F-fluorothymidine.

Iommelli F, De Rosa V, Terlizzi C, Monti M, Panico M, Fonti R, Del Vecchio S.

Clin Cancer Res. 2018 Jul 1;24(13):3126-3136. doi: 10.1158/1078-0432.CCR-17-3657. Epub 2018 Apr 4.

9.

The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study.

Faggiano A, Modica R, Severino R, Camera L, Fonti R, Del Prete M, Chiofalo MG, Aria M, Ferolla P, Vitale G, Pezzullo L, Colao A.

Endocrine. 2018 Oct;62(1):46-56. doi: 10.1007/s12020-018-1583-7. Epub 2018 Mar 23.

PMID:
29572709
10.

Metastasis to the Sellar/Suprasellar Region in a Patient With Endometrial Carcinoma Detected by 18F-FDG PET/CT.

Salvatore B, D'Amico D, Fonti R.

Clin Nucl Med. 2018 May;43(5):363-364. doi: 10.1097/RLU.0000000000002037.

PMID:
29485436
11.

Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapy.

Salvatore B, Klain M, Nicolai E, D'Amico D, De Matteis G, Raddi M, Fonti R, Pellegrino T, Storto G, Cuocolo A, Pace L.

Medicine (Baltimore). 2017 Oct;96(42):e8344. doi: 10.1097/MD.0000000000008344.

12.

Evaluation of metabolic response with 18F-FDG PET-CT in patients with advanced or recurrent thymic epithelial tumors.

Segreto S, Fonti R, Ottaviano M, Pellegrino S, Pace L, Damiano V, Palmieri G, Del Vecchio S.

Cancer Imaging. 2017 Mar 7;17(1):10. doi: 10.1186/s40644-017-0112-x.

13.
14.

Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma.

De Luca S, Fonti R, Camera L, Salvatore B, Faggiano A, Ciarmiello A, Segreto S, Colao A, Salvatore M, Del Vecchio S.

Ann Nucl Med. 2016 Apr;30(3):234-41. doi: 10.1007/s12149-015-1056-5. Epub 2016 Jan 11.

PMID:
26753628
15.

Detection of Leptomeningeal Involvement by 18F-FDG-PET/CT in a Patient With Non-Hodgkin Lymphoma.

Fonti R, Salvatore B, De Renzo A, Nicolai E, Del Vecchio S.

Clin Nucl Med. 2016 Feb;41(2):169-72. doi: 10.1097/RLU.0000000000001060.

PMID:
26545028
16.

Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1).

Lastoria S, Marciello F, Faggiano A, Aloj L, Caracò C, Aurilio M, D'Ambrosio L, Di Gennaro F, Ramundo V, Camera L, De Luca L, Fonti R, Napolitano V, Colao A.

Endocrine. 2016 Jun;52(3):488-94. doi: 10.1007/s12020-015-0702-y. Epub 2015 Aug 5.

PMID:
26242621
17.

Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non-Small Cell Lung Cancer.

De Rosa V, Iommelli F, Monti M, Fonti R, Votta G, Stoppelli MP, Del Vecchio S.

Clin Cancer Res. 2015 Nov 15;21(22):5110-20. doi: 10.1158/1078-0432.CCR-15-0375. Epub 2015 Jul 27.

18.

18F-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study.

Fonti R, Pace L, Cerchione C, Catalano L, Salvatore B, De Luca S, Pane F, Salvatore M, Del Vecchio S.

Clin Nucl Med. 2015 Apr;40(4):303-8. doi: 10.1097/RLU.0000000000000696.

PMID:
25608167
19.

Prognostic role of 18F-FDG PET/CT in the postoperative evaluation of differentiated thyroid cancer patients.

Pace L, Klain M, Salvatore B, Nicolai E, Zampella E, Assante R, Pellegrino T, Storto G, Fonti R, Salvatore M.

Clin Nucl Med. 2015 Feb;40(2):111-5. doi: 10.1097/RLU.0000000000000621.

PMID:
25546215
20.

Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic vipoma.

Camera L, Severino R, Faggiano A, Masone S, Mansueto G, Maurea S, Fonti R, Salvatore M.

World J Radiol. 2014 Oct 28;6(10):840-5. doi: 10.4329/wjr.v6.i10.840.

Supplemental Content

Loading ...
Support Center